COMMUNIQUÉS West-GlobeNewswire
-
TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial
27/05/2026 -
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
27/05/2026 -
Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
27/05/2026 -
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
27/05/2026 -
Reprogram Biosciences Closes Seed Financing to Advance Tumor Cell Reprogramming Therapeutics
27/05/2026 -
HNL Lab Medicine Receives Accreditation from the College of American Pathologists
27/05/2026 -
Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
27/05/2026 -
Intravacc obtient l’agrément CIR en France pour accompagner ses partenariats en R&D vaccinale
27/05/2026 -
Zealand Pharma to Present Data at the American Diabetes Association's 2026 Scientific Sessions
27/05/2026 -
Intravacc Secures French CIR Approval to Support Vaccine R&D Partnerships
27/05/2026 -
Bonito Biosciences and DaltonTx Announce AI-Driven Collaboration to Advance Precision Delivery for Oligotherapeutics
27/05/2026 -
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
27/05/2026 -
New study reveals promising new way to find serious liver disease earlier
27/05/2026 -
Remarcate Limited Liability Company Expands Into U.S. Market to Support Hispanic Healthcare Providers With AI-Driven Patient Acquisition Systems
27/05/2026 -
Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management
27/05/2026 -
argenx to Present at Upcoming Investor Conferences
27/05/2026 -
Vireo Growth Inc. Exercises Option to Purchase New York Facility from Innovative Industrial Properties
27/05/2026 -
Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC
27/05/2026 -
Inventiva publie ses informations financières du premier trimestre 2026¹
26/05/2026
Pages